Theriva Biologics TOVX
NYSE TOVX
$0.23 +0.02 (+9.52%)
As of: Sep 30, 2026 · 10:25 AM EDT

Theriva Biologics (TOVX) EBIT Margin (2010 - 2026)

Updated

Theriva Biologics' EBIT Margin was -709.00% in Q1 2026.

Analysis

Theriva Biologics (TOVX) EBIT Margin (2010 - 2026) Analysis & Trends

For FY2010, EBIT Margin at Theriva Biologics came in at -41.43%.

  • The Q1 2026 figure marks the highest quarterly EBIT Margin since Q3 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Theriva Biologics 10.10 Mn 10.10 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -709.00%
Sep 30, 2011 -319.76%
Jun 30, 2011 -258.61%
Sep 30, 2010 -252.89%
Jun 30, 2010 44.34%
API Access

Theriva Biologics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=TOVX&period=max&api_key=YOUR_API_KEY